Clinical Analysis of the Incidence and the Treatment of Pediatric Cataract Patients w ith Optic-nerve M aldevelopment

Cancan Lv，Wei Xiao

Shengjing Hospital of China Medical University， Shenyang 110004，China

Introduction

M aterials and methods

Participants

Surgical procedures

P-VEP exam ination

Adm inistration of m NGF

Statistical analysis

Results

The incidence of visual pathway disorder

The severity distribution of visual pathway disorders in groups 1 and 2

Table 1 Severity distribution of visual pathway disorders between groups 1 and 2 （41 cases， 69 eyes）

Table 2 Mean values of P100 latency between groups 1 and 2（ms，x±s）

Comparison of visual pathway function between groups 1 and 3

Table 3 Comparison of P100 latency between groups 1 and 3（ms，x±s）

Com parison of visual pathway function between congenital cataract eyes and contralateral eyes in group 2

Table 4 Mann-Whitney U tests of P100 latency between groups 1 and 3

Table 5 Test statistics

Com parison of visual pathway function before and after medication

Table 6 Comparison of P100 latency of congenital cataract eyes and contralateral eyes in group 2（n＝13， ms）

Table 7 P100 latencies （ms） of group 1 before and after medication and the date of mNGF injection

Table 8 P100 latencies （ms） of group 2 before and after medication and the date of mNGF injection

Table 9 Comparison of P100 latency of group 1 before and after medication（n＝20， ms）

Com parison of visual pathway function w ith and w ithout m NGF intervention in group 1

Table 10 Mean values of P100 latency of intervention and control group before medication （ms， ±s）

Table 10 Mean values of P100 latency of intervention and control group before medication （ms， ±s）

Note： t＝－0.621，P＝0.538

Groups Medication group （n＝20）Non-medication group （n＝22）No.of eyes 40 44 P100 latency （ms）138.64±20.75 143±24.37

Table 11 Mean values of P100 latency of intervention and control group after medication （ms，x±s）

Side-effects related to m NGF treatment

Discussion

Conclusion